KENUP-FOUNDATION
1.10.2020 10:10:11 CEST | Business Wire | Press release
On Wednesday, September 30, 2020, Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading Israeli regenerative medicine company developing a platform of novel biological products, and the Abu Dhabi Stem Cells Center (ADSCC) unveiled their first joint projects in a presentation at the Malta Conferences Foundation (MCF), a global conference supported by kENUP Foundation , a promoter of research-based innovation with public and societal benefit.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001005476/en/
Pluristem and ADSCC presented new projects, part of the recently signed Memorandum of Understanding aimed at harnessing the power of regenerative medicine.
The first joint project brings together the expertise of Pluristem and ADSCC to advance a potential COVID-19 treatment. The project will involve the first-time administration of Pluristem’s PLX cells via a nebulizer, a drug delivery device that helps a patient inhale medication through a mask or mouthpiece, to COVID-19 patients. The collaboration allows ADSCC to expand their stem cell therapy options using Pluristem’s PLX cells, while enabling Pluristem to leverage ADSCC’s nebulizer administration experience to develop a new treatment delivery model for PLX cells. ADSCC has reported effectively using nebulizers to treat COVID-19 patients with stem cells sourced from the patient’s own blood.
Further discussions for additional projects are underway, including for potential collaboration in chronic Graft Versus Host Disease (cGvHD), a life-threatening immune response of the donor’s stem cells against the host (patient).
The parties presented the joint projects to a distinguished audience at the MCF, including Nobel Laureates, scientists, and diplomats. The foundation’s mission is to address the shared desire to improve quality of life and political stability in the Middle East by identifying opportunities for collaboration to meet the scientific and technological challenges of the region.
“I am delighted for the opportunity to convene this important meeting. The Malta Conferences are the only platform in the world where scientists from 15 Middle East countries, Morocco and Pakistan can get together under the same roof with several Nobel Laureates. They develop collaborations and friendship which overcome the chasms of distrust and intolerance.” said Prof. Zafra Lerman, President of Malta Conferences Foundation.
“Embarking on this journey with Pluristem to overcome one of this generation’s most complex medical challenges marks an exciting new chapter full of possibilities when it comes to knowledge sharing and medical innovation. Our partnership speaks volumes about the power of collaboration between partners across previously divided borders. While we simply do not yet know the long-term impact the novel coronavirus will have on recovered patients, by working together we believe we are able to leverage the best medical technologies and minds in the region to develop solutions to prevent and treat the lingering symptoms and long-term complications that are emerging.” said Dr. Yendry Ventura, General Manager of ADSCC.
“We were very honored to unveil our first joint projects with the ADSCC at the MCF. We see our partnership as a movement between Israel and the UAE, which we hope will lay the foundation for future collaborations that will help potentially bring change to our region and the world. As we work together to develop regenerative medicine for key unmet medical needs of benefit to patients around the world, we are excited for the future and its possibilities,” stated Pluristem CEO and President Yaky Yanay.
‘Two world-class players in cell therapy join forces and cooperate on the fight of COVID-19. May this courageous cooperation serve as an example to the world’, says kENUP Foundation’s Executive Chairman Holm Keller.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201001005476/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Garvan Institute of Medical Research Joins Parse Biosciences’ Certified Service Provider Network15.7.2026 22:00:00 CEST | Press release
Researchers across Asia-Pacific gain a new option for high-quality single cell sequencing through Garvan's Evercode WT services Parse Biosciences, a QIAGEN company, and the leader in scalable and accessible single cell sequencing, today announced that the Genomics Platform Core Facility within the Garvan Institute of Medical Research has joined its Certified Service Provider (CSP) Program. The partnership broadens access to high-quality, scalable single cell sequencing across Australia, the wider Asia-Pacific region, and beyond. Garvan is one of Australia's preeminent medical research institutions, with the Genomics Platform having deep experience in cell sorting, capture, and sequencing. As a Certified Service Provider, Garvan will offer Parse's Evercode WT kits to researchers across the region. "We see a growing number of requests for Parse projects and find the technology easy to implement and run, generating great data," said Chris O'Keeffe, Cellular Genomics Lead at the Garvan Ins
Grafana Labs Named a Leader in 2026 Gartner® Magic Quadrant™ for Observability Platforms and Positioned Furthest in Completeness of Vision15.7.2026 20:21:00 CEST | Press release
Named a Leader for the third consecutive year and placed furthest in vision for the second year in a row, the company has had a landmark year of innovation as observability becomes essential infrastructure for teams building and running AI at scale. Grafana Labs, the company behind the open observability cloud, today announced it has been named a Leader in the Gartner® Magic Quadrant™ for Observability Platforms for the third consecutive year, and positioned furthest on the Completeness of Vision axis for the second year running. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715814984/en/ 2026 Gartner® Magic Quadrant™ for Observability Platforms We believe this placement reflects where the market is headed: toward open, composable observability that helps teams in the AI era understand systems that are increasingly complex and agentic, and rapidly scaling thanks to AI-assisted engineering. A Platform Built for the AI Era
Spectro Cloud Raises $100 Million Series D to Help Customers Move AI Infrastructure Into Production Across Enterprise, Public Sector, Neocloud and Sovereign Cloud Environments15.7.2026 18:20:00 CEST | Press release
Growth Equity at Goldman Sachs Alternatives leads oversubscribed round with strategic participation from AMD Ventures, Ericsson, LG Technology Ventures, and Maximus as organizations look to turn AI silicon into business outcomes Spectro Cloud, a leading provider of AI infrastructure management software, today announced it has raised more than $100 million in an oversubscribed Series D funding round led by Growth Equity at Goldman Sachs Alternatives, with strategic participation from AMD Ventures, Ericsson, LG Technology Ventures, and Maximus. The new funding brings Spectro Cloud’s total capital raised to $260 million and will accelerate the company’s mission to help enterprises, public sector organizations, neoclouds and sovereign clouds build and operate production AI infrastructure with greater control over cost, security and governance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715551858/en/ Spectro Cloud raises $
K-Beauty Goes Global: Sales Surge 53% as Korean Innovation Reshapes Beauty Growth15.7.2026 16:00:00 CEST | Press release
New NIQ data shows K-Beauty value sales rose 53% year-over-year and 131% over two years, underscoring how regional beauty trends, social commerce and ingredient-led innovation are reshaping global beauty growth. NIQ (NYSE: NIQ), a global leader in consumer intelligence, today released new findings showing K-Beauty has become a rapidly growing global beauty segment, with value sales up 53% year-over-year and 131% over the past two years. The data points to a broader shift in beauty growth, as regional innovation, social commerce and digitally driven consumer demand increasingly shape what scales globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715867578/en/ K-Beauty accelerates across global markets In its latest report, K-Beauty Goes Global, NIQ shows how Korean beauty is reshaping consumer expectations, accelerating innovation cycles and redefining competitive dynamics across the global beauty market. What began
Viz.ai to Support the MINUTE Trial, a Landmark Multicenter Study Evaluating the SCUBA Technique for the Treatment of Intracerebral Hemorrhage15.7.2026 15:00:00 CEST | Press release
Viz Neuro™ Suite, including Viz ICH™ and Viz ICH Plus™, to facilitate rapid detection and care coordination for patients with basal ganglia hemorrhage across trial sites nationwide. Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced its support for the Minimally Invasive Neurosurgery Trial for Ultra-early Treatment (MINUTE) Trial, a prospective, multicenter, randomized study evaluating whether the SCUBA technique, an endoscopic, catheter-based approach for ultra-early evacuation of basal ganglia intracerebral hemorrhage (BGH), is a promising alternative to standard medical management to potentially improve functional patient outcomes. The study aims to initiate both randomization and surgical intervention within 120 minutes of key clinical time points, reflecting the urgent nature of intracerebral hemorrhage care. Participating sites will have the ability to leverage the Viz Neuro Suite platform, including Viz ICH and Viz ICH Plus, to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom